60 µg dose hepatitis B vaccine

BIOLOGICAL4 trials

Sponsors

Shanxi Medical University, Suping Wang

Conditions

Hepatitis B VaccinationHepatitis B Vaccine

Phase 4

Immunogenicity of Hepatitis B Vaccination Among Drug Users

CompletedNCT02959775

Shanxi Medical UniversityHepatitis B Vaccination

Start: 2014-08-31End: 2015-10-31Updated: 2022-02-18

Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients

CompletedNCT02963714

Suping WangHepatitis B Vaccine

Start: 2014-12-31End: 2018-07-31Updated: 2022-02-14

Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients

CompletedNCT02991599

Shanxi Medical UniversityHepatitis B Vaccine

Start: 2014-10-31End: 2018-05-31Updated: 2021-12-23

Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults

CompletedNCT03316807

Suping WangHepatitis B Vaccine

Start: 2014-10-31End: 2018-07-31Updated: 2022-03-11

Related Papers

Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial.

2021-05-266 citations

Immunogenicity, antibody persistence, and safety of the 60 μg hepatitis B vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial

Expert Review of Vaccines2017-08-1429 citations

Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial.

2017-03-236 citations